Biopharmaceutical company AstraZeneca plc (AZN.L, AZN) announced Tuesday that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD). CKD affects an estimated 37 million people in the US.
from RTT - Biotech https://ift.tt/2ZtNiAo
via IFTTT
No comments:
Post a Comment